GlobeNewswire

Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL
13/04/2026
41.6% Absolute Difference in the Cema-Cel Arm Over the Observation Arm Exceeded Clinically Meaningful Benchmark Based on Literature of 25-30% MRD Reduction Occurred Rapidly Following Cema-Cel Treatment with a 97.7% [...]
Gelatide Drops Investigated (2026 Report) What Consumers Should Verify Before Buying
13/04/2026
A 2026 consumer-focused evaluation of Gelatide that analyses its marketing claims, ingredient profile, pricing structure, and key factors consumers should verify before making a purchase. Los Angeles, April 13, 2026 ( [...]
Leanzene Gummies Examined: 2026 Consumer-Focused Breakdown of Ingredients, Claims & Label Transparency
13/04/2026
NEW YORK, April 13, 2026 (GLOBE NEWSWIRE) -- As interest in metabolic support supplements grows, products like Leanzene Gummies are drawing attention among consumers exploring apple cider vinegar and BHB-based formulas [...]
Novo Nordisk A/S - share repurchase programme
13/04/2026
Bagsværd, Denmark, 13 April 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]
Regeneron and Telix Announce Strategic Radiopharma Collaboration
13/04/2026
Regeneron and Telix to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model Collaboration combines Regeneron’s leading antibody discovery/development [...]
Telix and Regeneron Announce Strategic Radiopharma Collaboration
13/04/2026
Telix and Regeneron to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model. Collaboration combines Telix’s expertise in radiopharmaceutical development [...]
ProSomnus® Receives FDA Class II Clearance for RPMO2 OSA Device
13/04/2026
SAN FRANCISCO, April 13, 2026 (GLOBE NEWSWIRE) -- ProSomnus Sleep Technologies (“the Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy® and pioneer in Smart Sleep Medicine™, today announced that the [...]
Major Shareholder Announcement
13/04/2026
April 13, 2026 Company Announcement No. 8 Major Shareholder Announcement COPENHAGEN, DENMARK and BOSTON, MA, USA, 13 April 2026 – BioPorto A/S (“BioPorto” or the “Company”) (CPH: BIOPOR) hereby announces, pursuant to [...]
Smart Minimalism, Supreme Efficiency: CUKTECH 15 Charging Station Makes Its Debut in Malaysia
13/04/2026
KUALA LUMPUR, Malaysia, April 13, 2026 (GLOBE NEWSWIRE) -- CUKTECH, a global leader in intelligent power solutions, today announced the official Malaysian launch of its highly anticipated flagship: the CUKTECH 15 [...]
Epitopea Strengthens Scientific Advisory Board with Appointment of Leading Authority in Cancer, Lisa Butterfield
13/04/2026
CAMBRIDGE, United Kingdom and MONTREAL, April 13, 2026 (GLOBE NEWSWIRE) -- Epitopea , a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies for hard-to-treat [...]
Epitopea renforce son comité consultatif scientifique avec la nomination de Lisa Butterfield, figure de renom dans le domaine du cancer
13/04/2026
CAMBRIDGE, Royaume-Uni et MONTRÉAL, 13 avr. 2026 (GLOBE NEWSWIRE) -- Epitopea , une société transatlantique spécialisée dans l'immunothérapie contre le cancer qui développe des immunothérapies à base d'ARN accessibles [...]
Boehringer Ingelheim introduces LENZELTA®: A new vaccine advancing mastitis prevention in dairy cows
13/04/2026
LENZELTA ® is a new vaccine significantly reducing the incidence and severity of clinical mastitis in vaccinated cows and heifers 1 . Administration is simple with two doses during the dry-off period. Mastitis continues [...]
Rising UK Dental Costs and NHS Access Crisis Drive Record Demand for Treatment in Türkiye — DentSpa Leads the Response
13/04/2026
ISTANBUL, April 13, 2026 (GLOBE NEWSWIRE) -- According to ad hoc data released by the ONS on 19 September 2025, approximately 523,000 UK residents now travel abroad annually for dental treatment — a 50.29% increase from [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
13/04/2026
COPENHAGEN, Denmark, April 13, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on March 12, 2026, under which the Company will repurchase shares for an amount up [...]
SynOx Therapeutics Announces Positive Topline Results from the Phase 3 TANGENT Study, Supporting Emactuzumab as a Differentiated, Next-generation Treatment for Patients with Tenosynovial Giant Cell Tumor (TGCT)
13/04/2026
TANGENT met its primary and secondary endpoints with a high level of statistical significance vs. placebo at 6 months, including ORR by RECIST V1.1 and Tumor Volume Score (TVS), and clinically meaningful improvements in [...]
Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria
13/04/2026
Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria Approval in CSU for children two to 11 years of age is based on data from the [...]
Communiqué de presse : Dupixent de Sanofi et Regeneron approuvé dans l'UE comme premier médicament ciblé contre l'urticaire chronique spontanée chez les jeunes enfants
13/04/2026
Dupixent de Sanofi et Regeneron approuvé dans l'UE comme premier médicament ciblé contre l'urticaire chronique spontanée chez les jeunes enfants L'approbation dans l'urticaire chronique spontanée (UCS) pour les enfants [...]
Roche receives CE mark for new Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis
13/04/2026
The Elecsys NfL blood test detects neuroaxonal damage associated with neuroinflammation in adults diagnosed with relapsing remitting multiple sclerosis. 1 This minimally invasive blood test enables greater patient [...]
Data Published in Nature Communications Highlights Unique Mechanism of Action of Alpibectir in Combination with Ethionamide (AlpE)
13/04/2026
BASEL, Switzerland, April 13, 2026 (GLOBE NEWSWIRE) -- BioVersys and partners publish in the prestigious journal of Nature Communications pre-clinical development data of AlpE (alpibectir and ethionamide), an innovative [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum